Free cash flow margin fell from 48.6% in 2025Q1 to 15.1% in 2026Q3 as capex rose to 21.7% of revenue and $500.0M went to net acquisitions, suggesting capital deployment has displaced buybacks as the primary use of cash.
United Therapeutics Corporation (UTHR) cash flow statement — 28-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 |
|---|
| Cash from Operations | 1.43B | 1.56B | 1.33B | 978M | 802.5M | 598.2M | 755.7M | -206.6M | 778.4M | 474.2M | 643.6M | 382.8M | 355.3M | 425.27M | 323.63M | 250.19M | 211.53M | 99.72M | -49.2M | 48.95M | 49.39M | 43.17M | 20.78M | -8.56M | -22.26M | -38.9M | -31.11M | -23.7M | -9.6M |
| Operating CF Margin % | - | 49.05% | 46.12% | 42.02% | 41.45% | 35.49% | 50.95% | -14.26% | 47.82% | 27.49% | 40.26% | 26.12% | 27.57% | 38.07% | 35.33% | 33.67% | 35.03% | 26.96% | -17.48% | 23.2% | 30.94% | 37.24% | 28.23% | -16.05% | -73.9% | -678.66% | -1518.35% | -5925% | -9600% |
| Operating CF Growth % | 20.04% | 17.64% | 35.7% | 21.87% | 34.15% | -20.84% | 465.78% | -126.54% | 64.15% | -26.32% | 68.13% | 7.74% | -16.45% | 31.41% | 29.35% | 18.28% | 112.12% | 302.71% | -200.51% | -0.89% | 14.41% | 107.75% | 342.68% | 61.53% | 42.78% | -25.02% | -31.29% | -146.88% | - |
| Net Income | 1.23B | 1.33B | 1.2B | 984.8M | 727.3M | 475.8M | 514.8M | -104.5M | 589.2M | 417.9M | 713.7M | 651.6M | 340.1M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.5M | -12.8M |
| Depreciation & Amortization | 96M | 85.6M | 72.5M | 53.2M | 51.3M | 49.9M | 49.9M | 45.9M | 35.9M | 31M | 31.6M | 32.9M | 32.2M | 31.26M | 27.14M | 20.54M | 17.92M | 11.39M | 4.54M | 957K | 1.46M | 2.41M | 2.28M | 2.33M | 3.13M | 3.51M | -79.74K | -1.3M | 0 |
| Stock-Based Compensation | 157.3M | 147.7M | 144M | 39.1M | 106.8M | 138.5M | 163.8M | 45.4M | -26.4M | 73.5M | 12.1M | 280.3M | 190.1M | 320.79M | 30.11M | -15.71M | 113.94M | 101.02M | 28.7M | 48.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 197.8M | 97.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185.11M | 104.34M | 136.23M | 81.43M | 41.92M | -1.04M | -34.39M | -3.28M | -37.05M | -18.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 41.1M | 2M | -24.3M | -1.3M | 58.3M | 108.2M | -35.9M | -15.1M | 55.3M | 30.2M | 3.6M | -379.9M | -191.71M | -93.36M | 33.89M | 57.33M | 6.64M | 20.18M | -7.75M | -15.57M | 16.31M | 2.11M | 1.64M | 2.14M | 11.4M | 2.06M | 42.83M | 9.3M | 2M |
| Working Capital Changes | -293.3M | -106.4M | -60.2M | -97.8M | -141.2M | -174.2M | 63.1M | -178.3M | 124.4M | -78.4M | -117.4M | -202.1M | -200.5M | -112.32M | -208.19M | -111.25M | -74.81M | -51.29M | 9.04M | -4.2M | -5.3M | -8.25M | 1.42M | -3.05M | -13.14M | -7.19M | 1.74M | 1.8M | 1.2M |
| Change in Receivables | -50.9M | -70.9M | -400K | -58.5M | -21.7M | -41.3M | -6M | 24.4M | 121.4M | -82.7M | -21.7M | -30.5M | -35.7M | -10.03M | -23.99M | -16.16M | -23.45M | -21.96M | -2.33M | -4.03M | -8.87M | -220K | 0 | 0 | -8.27M | -196.7M | 0 | 0 | 0 |
| Change in Inventory | -99.9M | -52.6M | -46.9M | -13.6M | -13.4M | -7.5M | 10.3M | 12.9M | 9.3M | -500K | -24.5M | -6.8M | -21M | -12.39M | -5.93M | -16.05M | -9.2M | -9.06M | -2.63M | -2.34M | -1.01M | -3.46M | -385K | -1.2M | -1.87M | -4.04M | -2.12M | 0 | 0 |
| Change in Payables | 96.7M | 97.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.2M | 600K | 16.97M | -6.75M | 7.51M | -37.21M | 16.66M | -2.73M | -3.65M | 18.51M | -1.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 93M | -551.3M | 417.2M | -719.6M | -811.5M | -486.9M | -738.5M | -335.4M | -820.6M | -835.6M | 48.3M | 503.6M | 338.5M | -294.97M | -163.36M | -121.33M | -209.24M | -160.52M | -172.48M | -21.71M | -104.03M | -71.28M | -12.87M | -47.54M | 120.36M | -134.78M | 7.16M | -24.1M | -11.5M |
| Capital Expenditures | -562.4M | -520.5M | -246.5M | -230.4M | -138.8M | -120.8M | -59.3M | -83.7M | -184.4M | -86.3M | -43.2M | -49.79M | -47.44M | -31.91M | -111.91M | -35.98M | -18.64M | -95.4M | -124.42M | -38.66M | -15.63M | -6.12M | -5.22M | -7M | -3.58M | -687.29K | -639.88K | -2.3M | -1M |
| CapEx % of Revenue | 17.64% | 16.35% | 8.57% | 9.9% | 7.17% | 7.17% | 4% | 5.78% | 11.33% | 5% | 2.7% | 3.4% | 3.68% | 2.86% | 12.22% | 4.84% | 3.09% | 25.79% | 44.2% | 18.33% | 9.79% | 5.28% | 7.09% | 13.13% | 11.89% | 11.99% | 31.22% | 575% | 1000% |
| Acquisitions | 0 | 0 | -30.5M | -89.2M | -1.5M | 0 | 0 | -20.5M | -129.1M | -60.3M | -43.3M | 0 | 0 | -30.77M | 0 | -3.55M | 0 | -3.57M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.13M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.28B | 1.85B | -28.5M | -23M | 3.5M | 0 | 2.4M | 0 | -46M | 8.3M | 0 | 350M | 0 | 30.77M | 0 | 0 | 13.9M | -2.1M | 0 | 0 | 0 | 0 | -179K | 4.18M | -5.41M | 40K | -3.87M | -100K | 0 |
| Cash from Financing | -1.67B | -1.15B | -1.25B | -11.9M | 75.4M | 44.8M | -16.9M | 611.2M | 6.3M | 43.3M | -497.7M | -447M | -576.6M | -5.12M | -169.14M | -218.08M | 146.76M | 36.48M | 213M | 20.88M | 74.13M | 14.17M | 6.32M | 2.01M | 185K | -2.88M | 206.61M | 59.3M | 22.9M |
| Debt Issued (Net) | 11.5M | -300M | -400M | -100M | 0 | 0 | -50M | 600M | 0 | 250M | -8.8M | -133.2M | -177.8M | -1.32M | -999K | -8.57M | 38.56M | 0 | -23K | -10K | 242.01M | -795K | -774K | -2.08M | -60K | -80K | -58.52K | 1.1M | 0 |
| Equity Issued (Net) | -1.65B | -816.9M | -1.01B | -13.8M | -11.4M | -10.8M | -3.7M | -2.1M | 0 | -250M | -500M | -394.5M | -483.1M | -42.44M | -188M | -212M | 0 | 0 | 150M | -67.06M | -178.64M | 14.96M | 7.09M | 4.08M | 245K | -2.8M | 206.51M | 58.4M | 22.9M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -29.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -2.06B | -1B | -1.01B | -13.8M | -11.4M | -10.8M | -3.7M | -2.1M | 0 | -250M | -500M | -394.5M | -483.1M | -42.44M | -188M | -212M | 0 | 0 | 0 | -67.06M | -193.09M | 0 | 0 | 0 | 0 | -2.8M | -4.07M | 0 | 0 |
| Other Financing | -39.6M | -33.1M | 157.4M | 101.9M | 86.8M | 55.6M | 36.8M | 13.3M | 6.3M | 43.3M | 11.1M | 80.7M | 84.3M | 38.64M | 19.86M | -5.04M | 108.2M | 36.48M | 63.05M | 58.34M | 10.76M | 0 | 0 | 0 | 0 | 0 | 159.42K | -200K | 0 |
| Net Change in Cash | -151.2M | -140.1M | 489.5M | 246.5M | 66.4M | 156.1M | 300K | 69.2M | -35.9M | -317.9M | 191.2M | 434.1M | 113.44M | 124.86M | -8.65M | -89.49M | 151.81M | -29.1M | -9.87M | 48.26M | 21.89M | -13.41M | 14.22M | -54.09M | 98.28M | -176.56M | 182.66M | 11.5M | 22.9M |
| Free Cash Flow | 867.2M | 1.04B | 1.08B | 747.6M | 663.7M | 477.4M | 696.4M | -290.3M | 594M | 387.9M | 600.4M | 333.01M | 307.86M | 393.36M | 211.72M | 214.22M | 192.89M | 2.22M | -173.59M | 10.43M | 36.15M | 37.58M | 15.56M | -15.57M | -25.84M | -39.59M | -31.75M | -26M | -10.6M |
| FCF Margin % | 27.21% | 32.7% | 37.55% | 32.12% | 34.28% | 28.32% | 46.95% | -20.04% | 36.49% | 22.48% | 37.55% | 22.72% | 23.89% | 35.22% | 23.11% | 28.82% | 31.94% | 0.6% | -61.67% | 4.94% | 22.65% | 32.42% | 21.15% | -29.18% | -85.79% | -690.65% | -1549.57% | -6500% | -10600% |
| FCF Growth % | -22.7% | -3.69% | 44.54% | 12.64% | 39.02% | -31.45% | 339.89% | -148.87% | 53.13% | -35.39% | 80.3% | 8.17% | -21.73% | 85.79% | -1.16% | 11.06% | 8573.2% | 101.28% | -1765.1% | -71.16% | -3.81% | 141.52% | 199.97% | 39.76% | 34.73% | -24.66% | -22.13% | -145.28% | - |
| FCF per Share | 19.14 | 21.73 | 22.28 | 15.04 | 13.68 | 10.09 | 15.61 | -6.63 | 13.50 | 8.64 | 12.83 | 6.50 | 5.68 | 7.39 | 3.97 | 3.61 | 3.24 | 0.04 | -3.79 | 0.23 | 0.75 | 0.75 | 0.33 | -0.37 | -0.63 | -0.98 | -0.83 | -0.97 | -0.64 |
| FCF Conversion (FCF/Net Income) | 0.70x | 1.17x | 1.11x | 0.99x | 1.10x | 1.26x | 1.47x | 1.98x | 1.32x | 1.13x | 0.90x | 0.59x | 1.04x | 2.44x | 1.06x | 1.15x | 2.00x | 5.12x | 1.15x | 2.46x | 0.67x | 0.66x | 1.34x | 0.86x | 0.94x | 1.04x | 0.41x | 0.71x | 0.75x |
| Interest Paid | 9.6M | 13.5M | 40.2M | 56M | 29.1M | 16.2M | 20.7M | 41M | 9.4M | 7.5M | 1.5M | 1M | 5.5M | 5.52M | 5.3M | 4.1M | 1.82M | 1.25M | 1.25M | 1.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 165.6M | 313.3M | 400.6M | 332.5M | 275.7M | 153.3M | 92.8M | 120.2M | 102.7M | 346.9M | 362.4M | 293.3M | 195.6M | 142.14M | 101.5M | 46.51M | 22.68M | 23.93M | 1.63M | 1.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying UTHR stock.
United Therapeutics Corporation (UTHR) generated $1.56B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
United Therapeutics Corporation (UTHR) generated $1.04B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
United Therapeutics Corporation (UTHR) spent $520.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, United Therapeutics Corporation (UTHR) spent $1.00B on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Lumpy operating cash conversion
Metrics are mathematically derived from official filings.
Operating Cash Conversion Swings Widely
According to reported quarterly figures, UTHR's operating cash flow to net income ratio ranged from 0.62 to 1.69 across the last ten quarters, with 2026Q3 at 1.19, indicating earnings quality that is timing-dependent rather than consistently cash-backed.
The ratio averaged near 1.1 over the period, meaning cash generation has broadly tracked profit, but the quarter-to-quarter dispersion is wide enough that single-period readings should not be relied upon. The 2025Q2 low of 0.62 and the 2026Q1 high of 1.69 are consistent with working capital timing, given the large swings in the working capital line, rather than a structural change in earnings quality. Investors should monitor whether conversion settles back toward the 1.0 to 1.2 band over the next several quarters.
Free Cash Flow Margins Compressing From Peak
Based on reported figures, UTHR's free cash flow margin fell from 48.6% in 2025Q1 to 15.1% in 2026Q3, as capital expenditure rose and operating cash flow lagged the earlier peak.
The decline reflects both a softer operating cash flow base and a higher capex load, with capex reaching $180.7M in 2026Q3 against roughly $75M to $100M in earlier 2025 quarters. The trend suggests the company's historically exceptional free cash generation is normalizing, which may indicate that the pipeline investment is absorbing a larger share of cash. Continued margin compression would warrant scrutiny of whether the spending is generating commensurate returns.
Rising Capital Intensity Tied to Pipeline
As reported in financial statements, UTHR's capex as a share of revenue climbed to 21.7% in 2026Q3 from 7.8% in 2025Q2, a material step-up in capital intensity for a business with historically light asset needs.
The increase is consistent with heavy investment in organ manufacturing and manufacturing infrastructure rather than maintenance of the treprostinil franchise, which carries modest physical asset requirements. Depreciation of $26.4M in the latest quarter remains far below capex, implying the asset base is expanding rather than being replaced. This pattern appears to reflect growth investment whose payoff is long-dated and unproven.
Acquisitions Absorb Cash Ahead of Buybacks
Based on UTHR's reported figures, net acquisition outflows totaled roughly $1.5B in 2026Q1 and $500.0M in 2026Q3, alongside a shift away from the earlier pattern of regular buybacks as the primary use of surplus cash.
The scale of recent acquisition outflows suggests management has redirected surplus cash toward external or pipeline assets, which may indicate a strategic move away from pure capital return. Dividends are absent in the reported periods, so shareholder returns depend entirely on repurchases, which have become less consistent. Whether these deployments generate adequate returns remains an open question warranting further investigation.
Cash Strength Masks Earnings Pressure
According to reported figures, UTHR's strong quarterly free cash flow in early 2026 coexists with an EPS decline of 20.3% year over year in 2026Q3, which may suggest the cash picture is flattered by working capital timing rather than underlying earnings momentum.
Stock-based compensation has been intermittently reported as zero, which may understate non-cash costs in some periods and should be treated as a data limitation rather than a conclusion. Strong operating cash flow in 2026Q1 at $463.3M appears inconsistent with the subsequent deceleration, reinforcing the view that timing effects drive much of the reported strength. Investors should not extrapolate the early-2026 cash figures as a run rate without confirming that working capital inflows are sustainable.